Navigation Links
Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
Date:9/15/2008

gets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expresse
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health ... of the flu virus, select Meijer pharmacies in ... for influenza and strep throat to eligible patients, enabling ... fill the matching prescriptions, under strict protocol set by ... Grand Rapids, Mich. -based retailer is ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers ... technologies must be able to protect their ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... of the Medical Device Industry, it steadfastly ... sectors of cases involving IP infringement. This ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Quality,Forum (NQF) announced today that Baylor Health Care ... National Quality Healthcare Award. The award,recognizes exemplary healthcare ... quality improvement in healthcare, and is,presented in partnership ... NQF National Quality Healthcare Award will be presented ...
... the state and ... in rural ... Shield,in Indiana announced the expansion of its Hoosier Healthwise network of,hospitals ... than 123,000 enrollees in the Hoosier Healthwise Medicaid,Managed Care program., ...
... MGT Capital Investments, Inc. (AMEX:,MGT), a holding ... sector, today announced that its subsidiary, Medicexchange ... the Chinese online business,Maydeal.com., The acquisition ... and offline business offerings in China.,The combined ...
... medicine may not be accurate, study finds , , ... of Web pages devoted to breast cancer contain inaccurate ... are 15 times more likely to make misleading claims ... , Moreover, standard measures of quality developed to assess ...
... KENSINGTON, Md., Feb. 11 "Psoriasis Cure,Now," a ... the,National Institutes of Health (NIH) for delivering a ... year 2007. Psoriasis research has,traditionally been underfunded at ... risen 159% (before inflation), but psoriasis and psoriatic,arthritis ...
... Continued Improvements in Medical Loss Ratio, SAN JUAN, ... GTS ), the largest managed care company in,Puerto Rico, ... income of $58.5 million and EPS of $2.15 for ... in net realized and unrealized,gains) reflecting the Company,s strong ...
Cached Medicine News:Health News:National Quality Forum Names Baylor Health Care System Winner of 2008 NQF National Quality Healthcare Award 2Health News:Anthem Blue Cross and Blue Shield Expands Network of Hospitals to Serve Hoosier Healthwise Members 2Health News:Anthem Blue Cross and Blue Shield Expands Network of Hospitals to Serve Hoosier Healthwise Members 3Health News:MGT Capital Investments, Inc. Announces Subsidiary's Preliminary Agreement to Acquire Maydeal.com 2Health News:Most Breast Cancer Web Pages Contain Reliable Information 2Health News:Psoriasis Cure Now Applauds Record Government Psoriasis Research Funding 2Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 2Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 3Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 4Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 5Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 6Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 7Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 8Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 9Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 10Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 11Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 12Health News:Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007 13
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: